Gastro Medical News about carcinomatosis

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal and gastrointestinal origin shows acceptable morbidity and high survival
European Journal of Surgical Oncology, 07/01/09

Hagendoorn J et al. - In a study to examine the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis of colorectal and gastrointestinal origin, it was concluded that in well-selected pts referred to a specialized institution, CS–HIPEC has acceptable morbidity and high survival rate.

Methods

67 pts underwent a laparotomy.
Complete cytoreduction could be performed in 49 pts, who underwent 53 CS–HIPEC procedures.
All had peritoneal carcinomatosis originating from primary colorectal, cecal, appendiceal, and gastric tumors.

Results

In pts who underwent CS–HIPEC, an R0 resection could be achieved in 4%, R1 in 88%, and R2 in 8%.
30-day mortality was 0; 1 pt died in-hospital after 10 wks.
Median hospital stay was 12 days.
Overall morbidity was 43%, including extended gastroparesis (11%), anastomotic failure (11%), and intra-abdominal abscess (9%).
Mean time to clinical recurrence was 12 mos.
Actuarial 1-yr survival was 88% and 2-yr survival was 75%.

<< Previous
Effectiveness of a Multidisciplinary Program for Management of...

Next >>
Rapid Infliximab Infusions in Pediatric Inflammatory Bowel...